Safety Study of Autologous Umbilical Cord Blood Cells for Treatment of

Status Completed

Clinical Trial Summary

This is a Phase I study to determine the safety and feasibility of injections of autologous umbilical cord blood (UCB) cells into the right ventricle of Hypoplastic Left Heart Syndrome (HLHS) children undergoing a scheduled Glenn surgical procedure. The investigators are doing this research study to find out if autologous stem cells from the individual's own umbilical cord blood can be used to strengthen the muscle of the right side of their heart. This will help determine the safety and feasibility of using cell-based regenerative therapy as an additional treatment for the management of HLHS.

Clinical Trial Description

This study is a Phase I trial to determine the safety of autologous mononuclear cells (MNC) derived from umbilical cord blood for intramyocardial delivery into the right ventricle during a planned and non-emergent Stage II surgical palliation in subjects with HLHS. This is the first critical step towards applying autologous MNC therapy as an add-on regenerative intervention for congenital heart disease management. The choice of HLHS as the target disease for regenerative therapies in congenital heart disease management is multi-factorial and includes the following considerations: 1) Severity of of this incurable disease, 2) palliative nature and burden of long-term outcomes with a single right ventricular system, 3) three stages of planned surgical procedures that provide time points to adjunctively intervene, and 4) prenatal diagnosis enabling planned collection of UCB. An emerging goal for cardiac regeneration includes the application of cell-based technology to congenital heart disease, which is a favorable substrate due to the lack of fibrotic scaring, and the presence of a microenvironment that is expected to support ongoing cardiac proliferation and growth for functional remuscularization. This Phase I safety study will determine the feasibility of collection, processing, and delivery of autologous cells as used in adult cardiac regenerative protocols in the setting of HLHS surgical management. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01883076
Study type	Interventional
Source	ReGen Theranostics, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	May 15, 2013
Completion date	April 28, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01215240` - Prophylactic Peritoneal Dialysis Decreases Time to Achieve a Negative Fluid Balance After the Norwood Procedure	N/A
Completed	`NCT00513240` - Erythropoetin Neuroprotection for Neonatal Cardiac Surgery	Phase 1/Phase 2
Withdrawn	`NCT00156455` - Sleep Disordered Breathing in Children With Single Ventricle Physiology	N/A
Terminated	`NCT01445041` - Safety and Feasibility Study of Umbilical Cord Blood Cells for Infants With Hypoplastic Left Heart Syndrome	Phase 1
Recruiting	`NCT04581668` - Impact of NAVA Ventilation on Brain Oxygenation and Perfusion in Children With Congenital Heart Disease	N/A
Completed	`NCT01736956` - Fetal Intervention for Aortic Stenosis and Evolving Hypoplastic Left Heart Syndrome	N/A
Completed	`NCT01708863` - A Prospective Study of Patients With Hypoplastic Left Heart Syndrome (HLHS) Following Stage II Surgical Palliation
Recruiting	`NCT03406884` - The CHILD Trial: Hypoplastic Left Heart Syndrome Study.	Phase 1
Active, not recruiting	`NCT03079401` - Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle	Phase 1/Phase 2
Completed	`NCT02306057` - Fluid Balance in Children Undergoing Fontan Surgery	N/A
Terminated	`NCT01107990` - Global and Regional Myocardial Strain and Power Output In Patients With Single Ventricles Using Novel MRI Techniques
Completed	`NCT04056416` - Physical Activity Promotion in Children and Adolescents With Single Ventricle Physiology (MedBike)	N/A
Completed	`NCT01656941` - Genetic Determinants of Congenital Heart Disease Outcomes
Completed	`NCT00464100` - Near-infrared Spectroscopy (NIRS) Neurodevelopmental Outcomes
Active, not recruiting	`NCT03779711` - Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome	Phase 2
Recruiting	`NCT04925024` - Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.	Phase 2
Recruiting	`NCT02781922` - Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)	Phase 3
Completed	`NCT01582529` - SVRII Family Factors Study
Completed	`NCT00974025` - Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients	N/A
Completed	`NCT00734643` - Family Adaptation Study Following the Diagnosis of Hypoplastic Left Heart Syndrome in a Newborn

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety Study of Autologous Umbilical Cord Blood Cells for Treatment of Hypoplastic Left Heart Syndrome

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms